Log in to search using one of your social media accounts:

 

Next Steps for Immunotherapies, Cell Therapies in Oncology Next Steps for Immunotherapies, Cell Therapies in Oncology

At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Thoracic oncologists Drs Jack West and Hossein Borghaei discuss critical questions in the treatment of low-expressing or PD-L1-negative non-small cell lung cancer patients.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
New research reports on three cases of a potentially vision-threatening eye condition called uveal effusion that patients developed after taking cancer immunotherapy.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Condition:   Urinary Bladder Cancer Interventions:   Drug: Nivolumab;   Radiation: Radiation therapy of the pelvis;   Procedure: Radical cystectomy with standardized pelvic lymphadenectomy Sponsors:   Technische Universität München;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Notice NOT-CA-18-074 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Authors: Sheahan AV, Biankin AV, Parish CR, Khachigian LM Abstract Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal app...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Ma J, Xu H, Wang S Abstract Lung cancer is the leading cause of cancer death worldwide due to its late diagnosis and poor outcome. Immunotherapy is becoming more and more encouraging and promising in lung cancer therapy. Myeloid-derived suppressor cells (MDSCs) are the main tumor suppressor factors, and the treatment strategy of targeting MDSCs is gradually emerging. In this review, we summarize what is currently known about the role of MDSCs in lung cancer. In view of the emerging importance of MDSCs in lung cancer, the treatment of targeting MDSCs will be useful to the control of the development and prog...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Notice NOT-CA-18-075 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Journal of Cutaneous Pathology, EarlyView.
Source: Journal of Cutaneous Pathology - Category: Pathology Authors: Source Type: research
AbstractBackgroundCancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls.MethodsAll melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to histor...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Case report Source Type: research
More News: Cancer & Oncology | Health | Hematology | Immunotherapy